2014, Number 1
<< Back Next >>
Rev Mex Cel Mad Med Biorreg 2014; 1 (1)
Immunomodulatory effect of the administration of mesenchymal stem cells in patients with lupus erythematosus
Rubio CG
Language: Spanish
References: 12
Page: 14-16
PDF size: 247.27 Kb.
ABSTRACT
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiorgan involvement. By compromising the recognition of autologous antigens understood as immune tolerance, patients with this condition have an altered immune response, both innate and acquired, mechanisms directly involved in the pathogenesis of the disease. Currently the treatment is based on the suppression of the immune response and symptomatic treatment for affected organs and tissues. Regenerative medicine is a developing discipline that is based on the repair of damaged tissues using cell therapy, growth factors, cytokines, and sometimes, scaffolding and biocompatible polymers. One aspect of regenerative medicine is the therapy with mesenchymal stem cells (MSCs); now it is known that these not only generate different embryonic tissue lineage, but also anti-inflammatory activity is documented. The present project aims to evaluate the effect of autologous and allogeneic mesenchymal stem cells in patients with lupus erythematosus, showing different proteins in the inflammatory phase before and after treatment with mesenchymal stem cells.
REFERENCES
Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Villa M et al. Non myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006; 295: 527-535.
Carrion F, Nova E, Ruiz C, Díaz F, Inostroza C, Rojo D, Monckeberg G, Figueroa FE. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010; 19: 317-322.
Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol. 1999; 181: 67-73.
El-Badri NS, Hakki A, Ferrari A, Shamekh R, Good RA. Autoimmune disease: Is it a disorder of the microenvironment? Immunol Res. 2008; 41: 79-86.
Crow MK. Developments in the clinical understanding of lupus. Arthritis Res Ther. 2009; 11: 245.
Fan L, Lin C, Zhuo S, Chen L, Liu N, Luo Y, Fang J, Huang Z, Lin Y, Chen J. Transplantation with survivin- engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail. 2009; 11: 1023-1030.
Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol. 2009; 183 (6): 3561-3567.
Huston DP. The biology of the immune system. JAMA. 1997; 278 (22): 1804-1814.
Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009; 228 (1): 132-148.
Le Pottier L, Devauchelle V, Pers J, Jamin C, Youinou P. Themosaic of B-cell subsets (with special emphasison primary Sjögren’s syndrome. Autoimmun Rev. 2007; 6 (3): 149-154.
Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009; 182 (10): 5982-5993.
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001; 293: 2111-2114.